MediPro Direct Gets CGF Backing for Mobile Diagnostics

The Grant family built part of its diagnostics history inside a central laboratory. Its newest move sends the operating system in the opposite direction, toward a medical provider arriving wherever the patient happens to be.

CGF Holdings has made a strategic investment in MediPro Direct, a nationwide mobile diagnostics and specimen-collection company. The September 16, 2026 announcement does not disclose the amount, valuation, ownership stake, board changes, or detailed terms. It does identify the operating objective: expand MediPro Direct's provider network, improve its technology platform, and develop more partnerships across clinical trials, life insurance, specialty laboratories, senior care, wellness, and healthcare.

The investment matters because mobile diagnostics is a coordination business disguised as a local appointment. A national operator has to match the right professional to the right location, manage instructions and specimen handling, update the client, and deliver a consistent patient experience while the work itself happens across thousands of homes and offices.

What CGF Holdings invested in

MediPro Direct says it coordinates more than 15,000 background-checked mobile medical providers across all 50 states. Its services include specimen collection, health screenings, paramedical examinations, and related mobile healthcare work for clinical-trial sponsors, life insurers, pharmaceutical companies, specialty laboratories, senior-care organizations, and other healthcare customers.

That network sits on a software and quality-control layer. MediPro Direct's website describes Quality First as a real-time patient-feedback system, while its case-management portal supports ordering, tracking, scheduling, document exchange, status updates, feedback, and reporting. The company also offers an examiner application with step-by-step collection guidance and documented APIs for specimen-collection workflows.

The current announcement reports a network above 15,000 providers, while older company and LinkedIn pages still say more than 13,000. The newer number is the best available current figure, but it remains company-reported rather than independently audited. MediPro Direct has not published completed-visit volume, turnaround times, collection-error rates, patient-satisfaction results, revenue, profitability, or customer concentration.

Why CGF's diagnostics history matters

CGF describes itself as a family office that makes separately capitalized equity investments and can pursue either growth-equity or buyout structures. Its portfolio page labels MediPro Direct as an equity raise, although neither party disclosed the exact security, ownership position, or governance rights attached to this transaction.

The operating fit is more revealing than the financial label. CGF Managing Partner Joey Grant previously served as President and General Manager of ExamOne, a Quest Diagnostics business serving life-insurance and health-science markets. CGF also traces the Grant family's diagnostics history through LabOne, where W. Thomas Grant II served as Chairman and CEO.

Quest Diagnostics' contemporaneous announcement valued its planned 2005 acquisition of LabOne at $934M. Quest described LabOne as a national provider of diagnostic testing, life-insurance risk assessment, and paramedical examinations. That record gives CGF direct historical context for the logistics, service quality, laboratory relationships, and insurance workflows that meet inside MediPro Direct's model.

Ryan Janeway built around the handoff

MediPro Direct CEO Ryan Janeway began offering the service in 2006 after developing the Quality First system to evaluate mobile providers through patient feedback. The official company history says the tool helped Janeway identify a stronger provider network and bring mobile collection services to life, health, and clinical markets.

The company now positions technology as a way to coordinate people rather than replace them. Its stated provider requirements include licenses or certificates, background checks, training, and location tracking. Those controls speak directly to the risk inside a distributed model: the software can schedule the visit, but a qualified person still has to perform it correctly and move the specimen into the next clinical or laboratory workflow.

MediPro Direct and CGF have not named a current CTO, CFO, new board member, or broader executive group connected to the investment. They have also not published a hiring plan, technology roadmap, capital-allocation schedule, or expansion timetable, so the verified growth case remains directional rather than operationally quantified.

The home is becoming part of the diagnostics network

The market context is visible in clinical research. The U.S. Food and Drug Administration's guidance for trials with decentralized elements recognizes in-home visits, local healthcare providers, and remote specimen collection as possible components of a clinical trial. Moving selected activities closer to participants can reduce travel and site burden, while creating a larger coordination obligation around training, protocol compliance, data consistency, and sample handling.

MediPro Direct operates in that handoff between a centralized medical or research program and a person who needs something completed locally. The same network can support a clinical-trial blood draw, a life-insurance examination, a specialty-laboratory kit, or another mobile collection workflow. Each market has different rules, but all of them place commercial value on completing the visit without losing control of quality or information.

Buyout Desk independently classified the transaction as a platform investment in healthcare and pharma services. That framing fits CGF's stated intention to use MediPro Direct as a growth platform, while the absence of disclosed economics keeps the public case focused on operating fit rather than a financial return narrative.

What the investment changes

The capital gives MediPro Direct room to enlarge its provider network, strengthen the coordination platform, and pursue more commercial relationships. CGF brings experience from diagnostics businesses where national coverage and quality control are already joined at the hip, and Ryan Janeway brings two decades of building the mobile version of that system.

The next evidence should emerge from the handoffs the partnership is financing. Provider growth will matter alongside completed-visit volume, sample quality, turnaround, patient experience, integration reliability, and customer retention. None of those measures is public today, and the transaction announcement does not turn them into facts.

MediPro Direct's expansion will occur one local visit at a time, inside a national system that the patient, sponsor, insurer, laboratory, and provider each experience differently. CGF is backing the layer responsible for keeping those experiences connected as the network gets larger.